Oracle Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $424K | Hold |
2,412
| – | – | 0.25% | 19 |
|
|
2025
Q3 | $338K | Hold |
2,412
| – | – | 0.21% | 18 |
|
|
2025
Q2 | $303K | Hold |
2,412
| – | – | 0.21% | 14 |
|
|
2025
Q1 | $330K | Hold |
2,412
| – | – | 0.17% | 17 |
|
|
2024
Q4 | $369K | Hold |
2,412
| – | – | 0.2% | 18 |
|
|
2024
Q3 | $468K | Hold |
2,412
| – | – | 0.28% | 20 |
|
|
2024
Q2 | $559K | Hold |
2,412
| – | – | 0.52% | 19 |
|
|
2024
Q1 | $520K | Hold |
2,412
| – | – | 0.35% | 23 |
|
|
2023
Q4 | $624K | Hold |
2,412
| – | – | 0.38% | 20 |
|
|
2023
Q3 | $620K | Hold |
2,412
| – | – | 0.19% | 18 |
|
|
2023
Q2 | $687K | Hold |
2,412
| – | – | 0.51% | 22 |
|
|
2023
Q1 | $671K | Hold |
2,412
| – | – | 0.65% | 17 |
|
|
2022
Q4 | $668K | Hold |
2,412
| – | – | 0.56% | 16 |
|
|
2022
Q3 | $644K | Hold |
2,412
| – | – | 0.37% | 16 |
|
|
2022
Q2 | $492K | Hold |
2,412
| – | – | 0.15% | 22 |
|
|
2022
Q1 | $508K | Hold |
2,412
| – | – | 0.1% | 26 |
|
|
2021
Q4 | $579K | Hold |
2,412
| – | – | 0.08% | 26 |
|
|
2021
Q3 | $683K | Hold |
2,412
| – | – | 0.09% | 30 |
|
|
2021
Q2 | $835K | Hold |
2,412
| – | – | 0.12% | 28 |
|
|
2021
Q1 | $675K | Sell |
2,412
-1,276
| -35% | -$344K | 0.1% | 22 |
|
|
2020
Q4 | $903K | Hold |
3,688
| – | – | 0.11% | 18 |
|
|
2020
Q3 | $1.05M | Hold |
3,688
| – | – | 0.14% | 14 |
|
|
2020
Q2 | $987K | Sell |
3,688
-1,180
| -24% | -$355K | 0.13% | 17 |
|
|
2020
Q1 | $1.54M | Hold |
4,868
| – | – | 0.46% | 14 |
|
|
2019
Q4 | $1.44M | Sell |
4,868
-1,500
| -24% | -$416K | 0.27% | 18 |
|
|
2019
Q3 | $1.48M | Hold |
6,368
| – | – | 0.36% | 15 |
|
|
2019
Q2 | $1.49M | Hold |
6,368
| – | – | 0.32% | 15 |
|
|
2019
Q1 | $1.5M | Hold |
6,368
| – | – | 0.32% | 15 |
|
|
2018
Q4 | $1.93M | Hold |
6,368
| – | – | 0.6% | 14 |
|
|
2018
Q3 | $2.25M | Hold |
6,368
| – | – | 0.49% | 14 |
|
|
2018
Q2 | $1.85M | Hold |
6,368
| – | – | 0.45% | 15 |
|
|
2018
Q1 | $1.74M | Hold |
6,368
| – | – | 0.42% | 18 |
|
|
2017
Q4 | $2.03M | Hold |
6,368
| – | – | 0.4% | 18 |
|
|
2017
Q3 | $1.99M | Hold |
6,368
| – | – | 0.33% | 15 |
|
|
2017
Q2 | $1.73M | Hold |
6,368
| – | – | 0.27% | 15 |
|
|
2017
Q1 | $1.74M | Sell |
6,368
-355
| -5% | -$100K | 0.27% | 16 |
|
|
2016
Q4 | $1.91M | Hold |
6,723
| – | – | 0.32% | 15 |
|
|
2016
Q3 | $2.1M | Hold |
6,723
| – | – | 0.32% | 15 |
|
|
2016
Q2 | $1.63M | Hold |
6,723
| – | – | 0.38% | 17 |
|
|
2016
Q1 | $1.75M | Sell |
6,723
-1,000
| -13% | -$264K | 0.46% | 17 |
|
|
2015
Q4 | $2.37M | Hold |
7,723
| – | – | 0.41% | 20 |
|
|
2015
Q3 | $2.25M | Hold |
7,723
| – | – | 0.46% | 21 |
|
|
2015
Q2 | $3.12M | Hold |
7,723
| – | – | 0.38% | 24 |
|
|
2015
Q1 | $3.26M | Hold |
7,723
| – | – | 0.41% | 24 |
|
|
2014
Q4 | $2.62M | Hold |
7,723
| – | – | 0.34% | 26 |
|
|
2014
Q3 | $2.56M | Hold |
7,723
| – | – | 0.35% | 24 |
|
|
2014
Q2 | $2.44M | Sell |
7,723
-3,807
| -33% | -$1.15M | 0.3% | 26 |
|
|
2014
Q1 | $3.53M | Sell |
11,530
-73
| -0.6% | -$23.2K | 0.4% | 26 |
|
|
2013
Q4 | $3.24M | Hold |
11,603
| – | – | 0.45% | 21 |
|
|
2013
Q3 | $2.79M | Hold |
11,603
| – | – | 0.4% | 20 |
|
|
2013
Q2 | $2.5M | Buy |
+11,603
| New | +$2.48M | 0.43% | 21 |
|
Other funds holding BIIB
Oracle Investment Management's BIIB Position: Q4 2025 in Review
Oracle Investment Management held its Biogen (BIIB) position steady in Q4 2025 at 2,412 shares worth $424K. The position accounts for 0.25% of the portfolio, ranked #19.
Oracle Investment Management first reported a position in BIIB in Q2 2013 and has held it in 51 quarters since. The position peaked at $3.53M in Q1 2014. 998 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Oracle Investment Management held 2,412 shares of Biogen worth $424K as of Q4 2025.
- Oracle Investment Management left its Biogen share count unchanged in Q4 2025.
- Biogen made up 0.25% of Oracle Investment Management's portfolio in Q4 2025, its #19 holding.
- Oracle Investment Management first reported a position in Biogen in Q2 2013 and has held it in 51 quarters since.
- Oracle Investment Management's Biogen position peaked at $3.53M in Q1 2014.
- 998 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Oracle Investment Management's 13F filing for Q4 2025, filed 18 Feb 2026.